CTOs on the Move

Golden Sap

www.goldensap.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.goldensap.com
  • 8 rang Saint-Jean-Baptiste RR 2
    Sainte-AuríŠlie, QC CAN G0M 1M0
  • Phone: 860.289.4053

Executives

Name Title Contact Details

Similar Companies

Americare Medical Supply

At Americare Medical Supply, we are committed to the excellence in terms of our Quality Products, Standards of Service, and Pricing. Client satisfaction is our number one priority and we take pride in providing quality products that make a difference i...

Salix

Salix is committed to being the leading US specialty pharmaceutical company licensing, developing, and marketing innovative products to healthcare professionals to treat gastrointestinal disorders in patients.

Pharmaceutics International

Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii`s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer contract analytical development and support formulation and manufacturing of oral solid dosage forms. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.

Summit Spine & Joint Centers

For compassionate and convenient care, Summit Spine & Joint Centers is the pain clinic you can trust. We provide treatment for a wide range of conditions. Call us today at (770) 962-3642.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).